Issue Ebook
cover story
Latest Issue
2026Year32Volume3Issue
- Abstract：目的:评估芪明颗粒作为早期治疗非增殖型糖尿病视网膜病变 (NPDR) 伴神经损伤患者的疗效和安全性.方法:这是一项多中心、随机、非劣效性、阳性对照临床试验. 研究纳入NPDR 合并神经损伤患者, 无论是否伴有眼底异常, 均通过随机数字表以1: 1比例随机分配, 给予芪明颗粒4.5克或羟苯磺酸钙(CaD)0.5克, 每日3次口服, 持续24周. 主要终点指标为第24周视网膜神经纤维层 (RNFL) 厚度和中央凹无血管区 (FAZ) 面积较基线变化. 次要终点指标包括第12周 RNFL 厚度和 FAZ 面积较基线的变化、视觉功能问卷 (NEI-VFQ-25) 、健康调查问卷 (SF-36 量表) 、中医症候要素量表评分, 以及治疗 12 周和 24 周时全视野视网膜电图 (ERG) 异常、眼底异常和视力异常的发生率. 监测不良反应 (ADR) .结果:共纳入 82 例患者. 第24周, 芪明颗粒组和对照组视网膜神经纤维层 (RNFL) 厚度较基线的变化分别为-1.53±9.88 μm和-4.61±9.23 μm (差异为3.08μm [97.5% 置信区间: -2.11至8.25]) . 黄斑中心凹无血管区 (FAZ) 面积第24周较基线变化分别为-0.08±0.39 mm2和0.01±0.05 mm2 (差异为-0.09mm2[97.5% 置信区间: -0.26至0.08]) . 两个主要终点均达到了非劣效性. 次要终点方面, 包括第12周RNFL厚度和FAZ面积较基线变化、第 12 周和第 24 周时视网膜电图 (ERG) 、眼底检查和视力异常发生率, 以及第24周时 NEI-VFQ-25、SF-36 量表和中医症候要素量表评分, 两组比较, 差异均无统计学意义 (P>0.05) . 芪明颗粒组和CaD组分别有4例 (9.76%) 和1例 (2.44%) 患者出现不良反应 (ADR) , 均未发生严重不良反应.结论:芪明颗粒作为NPDR相关神经损伤的早期治疗, 在疗效和安全性方面均不劣于CaD组. (注册号: ISRCTN39825773)Keywords：Qiming Granule;non-proliferative diabetic retinopathy;nerve injury;randomized controlled trial;Chinese medicine0|0|0Updated：2026-02-14
- Abstract：Objective:To assess the efficacy and safety profile of Aurantii Fructus Immaturus flavonoid (AFIF) tablets in the treatment of patients with functional dyspepsia (FD).Methods:In this phase Ⅲ, randomized, controlled clinical trial, participants diagnosed with FD from 7 medical centers across China were assigned by stratified block randomization to either AFIF treatment group (3 AFIF tablets, 0.29 g per tablet) or placebo group on the same schedule in a 3:1 ratio. The primary endpoint was the complete disappearance of 4 core FD symptoms, including postprandial fullness, early satiety, upper abdominal pain, and upper abdominal burning, following a 4-week treatment regimen (3 times daily). Secondary endpoints included the individual symptom disappearance rates and gastric emptying function after 4 weeks, as well as the disappearance rates for all 4 individual symptoms of FD at 4 weeks after treatment. Subgroup analyses included 3 clinical symptoms and 4 Chinese medicine patterns. Safety assessments included monitoring treatment-emergent adverse events (AEs), serious adverse events (SAEs), intervention-related AEs, and any AEs leading to discontinuation.Results:Of the enrolled patients, 299 in the AFIF group and 99 in the control group were induded in the full analysis set (FAS) and safety set (SS). After 4 weeks of treatment, the complete disappearance of all 4 core FD symptoms was achieved in 31.44% (94 cases) of patients in the AFIF group compared to 6.06% (6 cases) in the placebo group (P <0.01). At 4 weeks after end of treatment, the rates of symptom disappearance were 23.43% (67 cases) in the AFIF group and 2.22% (2 cases) in the placebo group (P <0.01). Individual symptom disappearance rates were significantly higher in the AFIF group at both week 4 and 4 weeks after treatment (all P <0.01). Additionally, the patients in the AFIF group exhibited a significantly greater improvement in gastric emptying at 2 h post-meal [66.55% (50.03, 84.55)] compared to the placebo group [51.10% (44.75, 68.93), P = 0.027]. At weeks 4 and 4 weeks after treatment, in the FAS, the disappearance rates of all 4 core FD symptoms remained higher in the AFIF group compared to the placebo group (all P <0.05). The per protocol set results similarly aligned with those observed in the FAS. Intervention-related AEs were reported in 6.02% (18 cases) of the AFIF group and 8.08% (8 cases) in the placebo group, with no SAEs recorded in either group. The patients in the AFIF group showed significantly higher complete symptom resolution rates of all 4 core FD symptoms at 4 weeks and 4 weeks after treatment across most subgroups, compared to the placebo group (all P <0.05). All AEs related to AFIF Tablets were mild.Conclusion:AFIF tablets demonstrated robust efficacy in alleviating the symptoms of FD, with a favorable safety profile. (Registration No. CTR20132482)Keywords：Chinese medicine;Aurantii Fructus Immaturus;functional dyspepsia;phase Ⅲ trial;efficacy;safety;randomized controlled trial0|0|0Updated：2026-02-14
- Abstract：Objective:To investigate the inhibitory effects and underlying mechanisms of Qideng Mingmu Capsule (QD) on retinal neovascularization (RNV).Methods:Seven-day-old C57BL/6J mice were assigned to the following groups: control, oxygen-induced retinopathy (OIR), low-, medium-, high-dose QD (225, 450, and 900 mg/g daily), and angiopoietin 1 (Ang1), 20 mice in each group. Except for the control group, an OIR model was induced by exposing mice to a hyperoxic environment for 5 d (postnatal days 7–12), followed by a normoxic environment for 5 d (postnatal days 12–17). From day 12, the treatment groups received QD orally or Ang1 via binocular intravitreal injection. On day 17, hematoxylin and eosin staining and fluorescein isothiocyanate-dextran staining were performed to evaluate RNV growth. Immunofluorescence staining, immunohistochemistry, and Western blotting were used to analyze the expressions of Ang/tyrosine kinase with immunoglobulin and epidermal growth factor homology domain-2 (Tie2) signaling pathway, hypoxia-inducible factor-1α (HIF-1α), and retinal vascular maturation markers. In addition, the effects of QD on the viability of rat retinal microvascular endothelial cells (rRMECs) was assessed.Results:QD significantly inhibited RNV formation, reduced RNV density, increased the expressions of Ang1, Tie2, and phosphorylated protein kinase B, and decreased the expression of Ang2 (P<0.05 or P<0.01). QD also enhanced retinal vascular pericyte coverage, reduced HIF-1α expression, and increased vascular endothelial cadherin levels (P<0.05 or P<0.01). Furthermore, no adverse effects were observed on the viability of rRMECs after QD intervention.Conclusions:QD effectively inhibited RNV formation, promoted neovascular maturation and remodeling, and protected retinal function by modulating the Ang/Tie2 signaling pathway. Therefore, QD may serve as a promising therapeutic option for retinal neovascular diseases.Keywords：Qideng Mingmu Capsule;Chinese medicine;angiopoietin;tyrosine kinase receptor;retinal neovascularization;oxygen-induced retinopathy0|0|0Updated：2026-02-14
- Abstract：目的:基于肝脏线粒体功能的保护, 评估三仁汤 (SRD) 对高脂饮食诱导的代谢功能障碍相关脂肪性肝病 (MASLD) 的影响.方法:采用分层随机法根据体重将36只雄性C57BL/6小鼠分为4组: 对照组、高脂饮食 (HFD) 组、SRD低剂量 (10.09 g/kg) 组和SRD高剂量 (20.18 g/kg) 组, 每组9只. 通过连续16周HFD饲喂建立小鼠MASLD模型. 采用苏木精-伊红 (HE) 染色和油红O染色观察肝组织病理变化. 检测肝脏组织甘油三酯 (TG) 、血清丙氨酸氨基转移酶 (ALT) 、空腹血糖 (FBG) 及空腹血清胰岛素水平. 对肝脏代谢谱进行分析, 差异代谢物通过偏最小二乘判别分析筛选, 并使用京都基因和基因组百科全书 (KEGG) 进行通路富集分析. 应用透射电镜观察线粒体微观结构; 采用蛋白印迹法检测呼吸链复合物Ⅰ–Ⅴ的蛋白质表达, 并测定呼吸链复合物Ⅰ和复合物Ⅱ活性.结果:在HFD诱导的MASLD模型, SRD干预4周后明显改善小鼠肝脂肪变性、炎症和肝细胞气球样变 (P<0.05) . 高剂量SRD治疗明显降低肝脏TG和血清ALT水平, 并改善胰岛素敏感性 (P<0.05) . 低剂量SRD显著降低肝脏TG及FBG (P<0.05) . 代谢组学结果显示, 高剂量SRD组肝脏代谢物与HFD组存在差异, 三羧酸循环 (TCA) 途径被显著激活. 电镜观察发现, 高剂量SRD改善了线粒体形态, 并增强三磷酸腺苷生成和脂肪酸氧化活性 (两者均P<0.05) . 此外, 高剂量SRD明显降低肝组织中过氧化氢和丙二醛含量, 同时提高超氧化物歧化酶活性 (P<0.05) . 高剂量SRD上调线粒体复合物Ⅱ蛋白表达及活性, 并上调线粒体复合物I的蛋白表达 (P<0.05) .结论:SRD在MASLD中表现出保肝作用, 改善了肝脏形态, 代谢及线粒体功能, 表明其作为MASLD治疗策略的潜力.Keywords：Sanren Decoction;metabolic dysfunction-associated steatotic liver disease;mitochondrial function;metabolomic analysis;Chinese medicine1|0|0Updated：2026-02-14
- Abstract：Objective:To investigate therapeutic effects of Huanglian Jiedu Decoction (HLJDD) on metabolic-associated fatty liver disease (MAFLD) and explore its underlying mechanisms.Methods:Q-Orbitrap liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to identify the incoming blood compounds of HLJDD. In vivo, high-fat diet (HFD)-induced MAFLD rats received HLJDD (5.4, 2.7, 1.35 g/kg) or silybin (37.8 mg/kg) once daily for 6 weeks. The rats fed with normal diets were served as control. Serum lipids were biochemically determined; and hepatic steatosis and lipid accumulation were evaluated with H&E and Oil red O stainings. In vitro, palmitic acid (PA)-treated HepG2 cells were co-incubated with 10% HLJDD drug-containing serum. Intracellular triglyceride (TG), total cholesterol (TC) and nonesterified fatty acids (NEFA) levels were detected and lipid droplet changes in HepG2 cells were observed by Oil red O staining. RT-qPCR and Western blot were employed to assess the expressions of lipid metabolic-related genes [diacylglycerol acyltransferase 2 (DGAT2), stearoyl-coenzyme A desaturase 1 (SCD1)] and components of the inositol-requiring enzyme 1alpha/X-box-binding protein-1 spliced (IRE1α/XBP1s) signaling pathway.Results:A total of 43 active compounds of HLJDD were identified. In HFD-fed rats, HLJDD treatment significantly improved hepatic TG and TC and increased HDL-C level (P<0.05 or P<0.01), and also markedly reduced serum levels of TG, TC, LDL-C, ALT, and AST (P<0.05 or P<0.01). H&E and Oil red O stainings further revealed that HLJDD effectively alleviated hepatic steatosis and attenuated lipid accumulation in the liver tissues. In PA-treated HepG2 cells, HLJDD treatment significantly reduced intracellular levels of TG, TC, and NEFA (P<0.05 or P<0.01), as well as lipid accumulation. More importantly, HLJDD treatment exerted therapeutic effects in both HFD-fed rats and PA-induced HepG2 cells by down-regulating lipid metabolic-related genes DGAT2, SCD1 and suppressing the IRE1α/XBP1s pathway related protein expressions (P<0.05 or P<0.01).Conclusion:HLJDD ameliorates MAFLD by modulating lipid metabolism through IRE1α/XBP1s signaling pathway, providing pharmacological evidence for its clinical application.Keywords：metabolic-associated fatty liver disease;Huanglian Jiedu Decoction;inositol-requiring enzyme 1alpha/X-box-binding protein-1 spliced signaling pathway;Chinese medicine0|0|0Updated：2026-02-14
- Abstract：Objective:To investigate the therapeutic effects of aqueous infusion of Cotinus coggygria Scop. leaves (CCLAI) on the dextran sulphate sodium (DSS)-induced ulcerative colitis (UC) in mice.Methods:A total of 56 C57BL16J mice were divided into 7 groups, including control, DSS model, CCLAI4, CCLAI6, DSS + CCLAI4, DSS + CCLAI6 and DSS + mesalamine groups (n=8). Induction of UC was conducted by 7-day treatment of 3% DSS in mice. CCLAI in 2 different doses (4% and 6%) or mesalamine (250 mg/kg) was administered to C57BL/6J mice orally for 7 consecutive days. The mice in the control group received only tap water. Clinical parameters, antioxidant and anti-inflammatory activities, and histopathological changes in the colon mucosa were examined. Cell proliferatipn index in colon section was determined by immunonistochemical analysis. Colonic cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS) expression levels were detected by Western blot.Results:CCLAI treatment inhibited DSS-induced colon shortening and significantly improved the Disease Activity Index score (P<0.05 or P<0.01). We also found a significant decrease in myeloperoxidase levels, oxidative stress parameters, and neutrophil infiltration index in the experimental groups receiving CCLAI compared to the control group (all P<0.01). In addition, it was observed that CCLAI administration for 7 days decreased the pro-inflammatory cytokines levels including interleukin (IL)-1β, IL-6, interferon-γ, and tumor necrosis factor-α in the colon tissues of mice receiving DSS (P<0.05). Further, CCLAI treatment reduced the COX-2 and iNOS levels with an accompanying decrease in prostaglandin E2 and nitric oxide levels, respectively. Additionally, CCLAI treatment markedly decreased the histological lesion score, which was consistent with the reduction of the pro-inflammatory cytokine levels.Conclusion:CCLAI treatment significantly improved the DSS-induced UC in mice by diminishing histopathological damage in the colonic mucosa and markedly decreased the inflammatory response through inhibiting the formation of inflammatory cytokines and markers of oxidative stress.Keywords：Cotinus coggygria Scop;antioxidant activity;anti-inflammatory activity;ulcerative colitis;dextran sulphate sodium2|0|0Updated：2026-02-14
- Abstract：Objective:To explore whether polysaccharide of Danggui Buxue Decoction (formula polysaccharide, FP) could attenuate colorectal cancer (CRC) via modulating intestinal microflora and metabolites.Methods:A total of 30 male C57BL/6 mice were randomly assigned to 3 groups according to body weight, including normal control, CRC model and FP groups (n=10). Dextran sulfate sodium and azoxymethane were used to induce CRC model. The mice in FP group were treated with FP [0.9 g/(kg•d)] for 8 weeks. Then the coloretal length, weight and tumors number of colorectal tissues were observed. Colonic tissues were stained with hematoxylin and eosin to evaluate the histological changes. Tight junction proteins including claudin 1 and zonula occludens-1 (ZO-1) were detected using immunohistochemistry. Serum concentrations of endothelial cell specific molecule-1 and carcino embryonic antigen were determined using enzyme-linked immunosorbent assays. Toll-like receptor 4 (TLR4)/nuclear transcription factor-κB (NF-κB) p65 signal-related mRNA and proteins expressions were detected using real-time polymerase chain reaction and Western blot, respectively. Feces samples were detected with 16S rRNA and liquid chromatography-mass spectrometry and non-targeted metabolomics sequencing was used to analyze the composition of intestinal microbiota and metabolic changes.Results:FP significantly inhibited colorectal tumor growth, attenuated body weight loss, repaired colonic structure, improved intestinal barrier dysfunction, reduced colonic inflammatory cytokine levels and inhibited TLR4/NF-κB pathway related mRNA and protein expressions (all P<0.01). Moreover, FP altered the gut microbiota composition of CRC mice dramatically, characterized by a reduction of Firmicutes-Bacteroidetes ratio at the phylum level. FP suppressed Lachnospiraceae_NK4A136_group, Odoribacter and Romboutsia (P<0.05 or P<0.01), and elevated the abundance of Dubosiella, Candidatus_Saccharimonas and Alloprevotella at the genus level (P<0.01). Non-targeted metabolomics sequencing detected significant differences in metabolites, and the functions of differential metabolites were focused on regulating amino acid metabolism, lipid metabolism and metabolism of cofactors and vitamins.Conclusions:FP attenuates colonic injury and intestinal inflammatory response in CRC mice, repairs disrupted-intestinal microbiota, and improves metabolites. This research provides experimental basis for application of FP as a potential therapeutic agent for CRC.Keywords：Danggui Buxue Decoction;polysaccharide;colorectal cancer;intestinal microflora;metabolites;Chinese medicine0|0|0Updated：2026-02-14
Original Article
- Abstract：Objective:To evaluate the effects and safety of auricular acupressure combined with periocular thumbtack needle (AATN) therapy for premyopia children.Methods:This multi-center, randomized, controlled trial was conducted in 8 Chinese hospitals, and 298 premyopic children aged 6 to 10 years were recruited between October 2020 and February 2022. Eligible participants were randomly assigned to the treatment group or the control group via a simple randomization method. All the participants in both groups were provided with standard intensive eye health instruction through phone calls, WeChat or hospital visits once a week, and the children in the treatment group received AATN therapy additionally. Following 12-week treatment, participants were followed up at 3-month intervals, with the entire study extending over a 9-month duration from baseline to the final assessment. The primary outcome was the mean change in spherical equivalent (SE) from baseline to 36 weeks. The secondary outcomes included the rate of children with stable myopia (MSR), uncorrected visual acuity (UCVA), axial length (AL), corneal curvature (CC), accommodative amplitude (AMP) and intraocular pressure (IOP) at baseline, 6,12, 24 and 36 weeks. Safety assessment included analysis of treatment-related adverse events (AEs), such as allergic reactions and skin damage.Results:Totally, 298 children with premyopia were included, 151 in the treatment group and 147 in the control group. At the 36th week, the SE was –0.81±0.55 D in the control group and –0.65±0.44 D in the treatment group (P=0.002). The treatment group demonstrated superior SE control efficacy compared with the control group, with differences of –0.29±0.37 D and –0.49±0.44 D, respectively (P<0.01). The children in the treatment group achieved a MSR of 57.78% with more favorable outcome than 37.10% in the control group (P<0.01). The adjusted mean change in AMP from baseline to 9th month was 8.85±4.02 in the control group and 9.85±3.41 in the treatment group (P=0.018). AL increased by a mean of 0.35±0.28 mm in the control group and 0.20±0.42 mm in the treatment group (P=0.004). No significant differences in UCVA or CC were found between the two groups (P>0.05) and no AEs were reported.Conclusion:AATN therapy was effective for controlling the onset of myopia and SE, enhancing ocular accommodation, and mitigating AL. (Registration No. ChiCTR2000039299)Keywords：myopia;Chinese medicine;auricular acupressure;thumbtack needle;children;randomized controlled trial2|0|0Updated：2026-02-14
Acupuncture Research
Herbal and Botanical Review
Review
- 邮编：100091
- 联系电话：010-62886827, 62877592 传真：010-62874291
- 技术支持由北京北大方正电子有限公司提供 京ICP备05067934号-1
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
0